India, June 22 -- Eli Lilly And Co.'s (LLY) investigational oral GLP-1 receptor agonist, orforglipron, demonstrated compelling efficacy and a safety profile aligned with that of injectable GLP-1 therapies, according to full Phase 3 results published in The New England Journal of Medicine.
The once-daily pill significantly reduced A1C levels by an average of 1.3% to 1.6% across doses in adults with type 2 diabetes, with improvements observed as early as four weeks. In the ACHIEVE-1 study, a key secondary endpoint showed that orforglipron achieved an average weight loss of 16.0 pounds (7.9%) at the highest dose by week 40. The safety findings were consistent with the broader GLP-1 class profile.
ACHIEVE-1 is a phase 3 trial, which evaluated...